Alkermes plc stock launches inaugural research awards program amid biotech innovation push

robot
Abstract generation in progress

Alkermes plc has launched the inaugural Alkermes Pathways (APN) Research Awards program to fund neuroscience research, building on strong 2024 financial results. This initiative aims to accelerate discoveries in CNS disorders and expand the company’s R&D, attracting investor interest in its Nasdaq-listed stock. The program complements Alkermes’ existing pipeline and strengthens its position as an innovation leader in the biotech sector.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin